Partner Irfan Lateef was quoted in “A Post-IPR World Would Hold Patent Risks And Benefits For Medtech Companies”, an article posted in Medtech Insight.
Excerpt: The inter partes review process, which provides a non-court strategy for invalidating patents, could conceivable come to an end depending on the Supreme Court’s ruling in a case this spring. Device firms have been wary fo the IPR process, which can weaken patent protections, but attorneys point out that it has also been a helpful tool in fighting against the growing threat of patent trolls in medtech. While bets are for upholding the system, legal experts say device companies could fall back to other processes previously used to stop patent trolls.
Read full article here >> (Subscription Required)
